822 related articles for article (PubMed ID: 15139073)
1. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
2. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.
Erazo Valle A; Wisniewski T; Figueroa Vadillo JI; Burke TA; Martinez Corona R
Curr Med Res Opin; 2006 Dec; 22(12):2403-10. PubMed ID: 17257454
[TBL] [Abstract][Full Text] [Related]
3. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
4. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
[TBL] [Abstract][Full Text] [Related]
5. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.
Majem M; Moreno ME; Calvo N; Feliu A; Pérez J; Mangues MA; Barnadas A
Support Care Cancer; 2011 Dec; 19(12):1983-90. PubMed ID: 21086141
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study.
López-Jiménez J; Martín-Ballesteros E; Sureda A; Uralburu C; Lorenzo I; del Campo R; Fernández C; Calbacho M; García-Belmonte D; Fernández G
Haematologica; 2006 Jan; 91(1):84-91. PubMed ID: 16434375
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
8. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy.
Rogers MP; Blackburn L
Clin J Oncol Nurs; 2010 Aug; 14(4):500-4. PubMed ID: 20682506
[TBL] [Abstract][Full Text] [Related]
9. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
12. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
[TBL] [Abstract][Full Text] [Related]
15. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
18. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
[TBL] [Abstract][Full Text] [Related]
19. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
20. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
